NCT01629758已完成1 期
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb10 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2012年6月最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 10
- 主要终点
- Safety, as measured by the rate of adverse events and serious adverse events
研究概览
简要总结
The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All subjects will have locally advanced or metastatic solid tumors
- •For Part 2 (Cohort Expansion):
- •Tumor types will be restricted to clear cell renal cell carcinoma (ccRCC), non-small cell lung cancer (NSCLC), and melanoma
- •At least 1 lesion with measurable disease
- •Only subjects with tumor samples that are PD-L1 positive or negative are eligible
排除标准
- •Uncontrolled central nervous system (CNS) or leptomeningeal metastasis
- •Inadequate liver or kidney function
- •History of autoimmune Disease
结局指标
主要结局
Safety, as measured by the rate of adverse events and serious adverse events
时间窗: Approximately up to 4.5 years
次要结局
- Efficacy as measured by tumor assessment (RECIST)(Week 6 of for the first 4 cycles, Week 6 of alternate cycle starting with cycle 6, End of Treatment (2 years) and approximately every 12 weeks during follow-up (approximately 1 year))
- Immunogenicity as measured by incidence of specific antidrug antibodies (ADA) to BMS-98470 and BMS-936558(Up to 2 years + 100 days post-treatment follow-up)
研究者
研究点 (10)
Loading locations...
相似试验
终止
1 期
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid TumorsHead and Neck CancerNeoplasm MetastasisColorectal CancerNCT00908024Bristol-Myers Squibb54
已完成
1 期
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid TumorsCancerTumorNCT00329004Bristol-Myers Squibb89
已完成
1 期
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCancerMelanomaNCT03400332Bristol-Myers Squibb281
已完成
1 期
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast CancerBreast CancerNCT00788333Bristol-Myers Squibb40
招募中
1 期
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)Non-small Cell Lung Cancer (NSCLC)NCT06476808Bristol-Myers Squibb240